BR100 Increased By (0.46%)
BR30 Increased By (0.7%)
KSE100 Increased By (0.48%)
KSE30 Increased By (0.44%)
AGHA 6.50 Increased By ▲ 0.05 (0.78%)
BECO 4.14 Decreased By ▼ -0.02 (-0.48%)
BML 58.80 Increased By ▲ 1.49 (2.6%)
BOP 28.29 Increased By ▲ 0.14 (0.5%)
CNERGY 12.54 Increased By ▲ 0.13 (1.05%)
CSIL 5.35 Decreased By ▼ -0.01 (-0.19%)
FCCL 51.30 Decreased By ▼ -0.36 (-0.7%)
FFL 13.91 Increased By ▲ 0.01 (0.07%)
FNEL 1.09 Increased By ▲ 0.01 (0.93%)
KEL 5.74 Increased By ▲ 0.02 (0.35%)
KOSM 5.31 Decreased By ▼ -0.02 (-0.38%)
LOTCHEM 24.17 Decreased By ▼ -0.08 (-0.33%)
MLCF 89.70 Increased By ▲ 0.06 (0.07%)
NBP 156.99 Increased By ▲ 0.42 (0.27%)
NCPL 51.72 Increased By ▲ 4.70 (10%)
NPL 57.16 Increased By ▲ 5.20 (10.01%)
OGDC 302.71 Increased By ▲ 2.70 (0.9%)
PACE 9.34 Increased By ▲ 0.08 (0.86%)
PAEL 33.05 Increased By ▲ 0.04 (0.12%)
PIBTL 13.14 Decreased By ▼ -0.05 (-0.38%)
PPL 216.30 Increased By ▲ 1.98 (0.92%)
PRL 99.90 Decreased By ▼ -1.54 (-1.52%)
PTC 52.17 Decreased By ▼ -0.07 (-0.13%)
SSGC 23.21 Increased By ▲ 0.06 (0.26%)
TBL 8.95 Decreased By ▼ -0.14 (-1.54%)
TELE 6.99 Increased By ▲ 0.01 (0.14%)
TPL 22.22 Increased By ▲ 0.18 (0.82%)
TPLP 11.46 Decreased By ▼ -0.23 (-1.97%)
TREET 23.21 Increased By ▲ 0.41 (1.8%)
TRG 56.89 Decreased By ▼ -0.24 (-0.42%)
اردو
Android App
Print Edition Dollar to PKR
Daily Petrol Prices IMF-World Bank meetings Intl Oil Prices Iran-US war Gold Rates Podcasts PSX Notices
World

AstraZeneca to supply COVID-19 antibody cocktail to Singapore

Published Updated
Save
1 min
Comments
By Reuters

SINGAPORE: AstraZeneca said on Friday it will supply Singapore with its COVID-19 antibody cocktail, Evusheld, by the end of the year.

Evusheld can act as another layer of protection, alongside vaccines, for people who are at high risk of COVID-19 infection, according to AstraZeneca's statement.

The company did not specify how many courses of the treatment would be supplied to the Southeast Asian city-state.

The US Food and Drug Administration on Wednesday authorised the use of Evusheld to prevent COVID-19 infections in individuals with weak immune systems or a history of severe side effects from coronavirus vaccines.

AstraZeneca

Comments

Comments are closed for this article.

More Stories

Browse all stories